The Prenatal Testing & Newborn Screening Market is growing at a significant rate owing to the increasing prevalence of the newborn diseases. With rising incidence of diseases, rapid innovations in technology in medical field, and government initiative in spending for research and development, the newborn screening market is expected to have tremendous growth. Lifestyle inclinations such as smoking, drinking, obesity, increasing maternity age, and genetic disorders are some of the factors responsible for the growth of the market. Prenatal Testing & Newborn Screening Market size is forecast to reach $15,729 million by 2027, growing at a CAGR of 11.2% during the forecast period 2022-2027.
Prenatal testing is used to determine the risk of whether the fetus of the mother will be born with any genetic abnormalities. It also analyzes the fragments of Deoxyribonucleic acid (DNA) that is circulating in pregnant blood. The rise in the adoption of cell-free DNA screening for predicting the risk of genetic conditions, growing adoption of ultrasound detection methods in hospitals, increase in the risk of chromosomal abnormalities with rising maternal age, and growing demand for chorionic villus sampling and amniocentesis in diagnostic laboratories are some of the factors that are set to drive the growth of the market. It is carried to check the presence of genetic disorders such as Tay-Sachs disease, cystic fibrosis, sickle cell anaemia and Down’s syndrome among others. Screening is further continued after a baby is born, called newborn genetic testing to check for genetically inherited diseases or congenital anomalies such as phenylketonuria (PKU), muscular spinal atrophy, critical congenital heart disease, hearing loss, and others. Prenatal and new-born genetic testing is significant in determination of various options during pregnancy to improvise the health outlook for the baby. Prenatal and newborn screening helps in prevention of infant mortalities and enhances patient outcomes.
North America dominated the global market share of the prenatal testing & newborn screening market in 2020 owing to the increasing research & development, and increasing penetration of improved medication. The demand for prenatal testing & newborn screening market is increasing along with the increasing availability of various treatments, increasing incidences of the diseases, and improving healthcare infrastructure. The rapid growth of the prenatal testing & newborn screening is driving the demand for prenatal testing & newborn screening market. All these factors are set to avail new growth opportunities to the prenatal testing & newborn screening market in the region during 2022-2027.
For More Queries About "Prenatal Testing and Newborn Screening Market" @ https://www.industryarc.com/support.php?id=15078
Prenatal Testing & Newborn Screening Market Growth Drivers:
Technological progressions and introduction of advanced products
With the emergence of advanced technologies such as next generation sequencing, high throughput screening, and cell free fetal DNA, there has been a steady growth in the overall demand of the newly developed prenatal diagnosis and newborn screening tests. The newborn screening has been a great example of how technology and research advance health, from the past six decades. In the early 2000s, disorders were screening for, on average, 4 conditions. Today, most states screen for over 30 conditions. This increase is owing to the advancements in technology and the advocacy efforts of families.
Government initiative by providing funds and prevalence of newborn diseases
Rising government initiatives in creating awareness regarding neonatal hereditary diseases has increased the demand for newborn screening in the global market. Intensification in funding from government organizations and technological advancements in tests are driving prenatal testing and newborn screening market. The legal approval of the prenatal testing and newborn screening in most of the states of the U.S., government investment & regulations along with the favorable reimbursement policies and shifting focus of the government towards providing improved healthcare facilities will have a positive impact on the prenatal testing &newborn screening market.
In March 2020, Agilent introduced Agilent GenetiSure Cyto microarrays that includes three novel microarrays to meet the requirements of institutions and laboratories engaged in prenatal and postnatal research. It helped the company in gaining competitive advantage and strengthening its industrial position. There was also a drop in in-person visits for patients electing for prenatal and new-born genetic testing. According to a research study conducted at the Cleveland Clinic Healthcare System, in 2020, COVID-19 pandemic was responsible for decline in prenatal and new-born genetic testing. A significant proportion of participants in the study postponed the testing procedure, in order to restrict visit to the over-burdened healthcare facilities.
The Major Players in this Market Include
The major companies in the Prenatal Testing & Newborn Screening market include Perkin Elmer, Progenity, Laboratory Corporation of America Holdings, Natera, Invitae, Centogene, Roche Diagnostics, Quest Diagnostics, Eluthia, and Agilent among others.
Over the years, major market players have focused on different prenatal testing & newborn screening that were typically used to treat various diseases. The launch of new market companies, adequate funding, and government-aided policies help in the development of prenatal testing & newborn screening. The continuous developments in the Prenatal Testing & Newborn Screening Market such as advanced technologies, increasing funding amount of startups and research organizations are the major factors set to drive the Prenatal Testing & Newborn Screening market during the forecast period 2022-2027.
To request for a quote, provide your details in the below link:
Mr. Venkat Reddy
Email: [email protected]
Contact Sales: +1-970-236-3677
About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.